Copyright © 2004 by the European Society of Cardiology.
ESC Expert consensus document
Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease
The Task Force on ACE-inhibitors of the European Society of Cardiology
Task Force Members,
| The first 150 words of the full text of this article appear below. |
ESC Committee for Practice Guidelines (CPG), Silvia G. Priori (Chairperson) (Italy), Maria Angeles Alonso García (Spain), Jean-Jacques Blanc (France), Andrzej Budaj (Poland), Martin Cowie (UK), Veronica Dean (France), Jaap Deckers (The Netherlands), Enrique Fernandez Burgos (Spain), John Lekakis (Greece), Bertil Lindahl (Sweden), Gianfranco Mazzotta (Italy), Keith McGregor (France), João Morais (Portugal), Ali Oto (Turkey), Otto A. Smiseth (Norway)
Document Reviewers, Maria Angeles Alonso García (CPG Review Coordinator) (Spain), Diego Ardissino (Italy), Cristina Avendano (Spain), Carina Blomström-Lundqvist (Sweden), Denis Clément (Belgium), Helmut Drexler (Germany), Roberto Ferrari (Italy), Keith A. Fox (UK), Desmond Julian (UK), Peter Kearney (Ireland), Werner Klein (Austria), Lars Köber (Denmark), Giuseppe Mancia (Italy), Markku Nieminen (Finland), Witold Ruzyllo (Poland), Maarten Simoons (The Netherlands) Kristian Thygesen (Denmark), Gianni Tognoni (Italy), Isabella Tritto (Italy), Lars Wallentin (Sweden)
Preamble
Guidelines and Expert Consensus documents aim to present all the relevant evidence on a particular issue in order to help physicians to weigh
Classes of recommendations
Levels of evidence
Introduction
Pharmacology
Definition
ACE-Inhibitor classification
Pharmacokinetic profile
Mechanism of action
Effects of ACE-inhibitors
Haemodynamic effects
Neurohormonal effects
Antiproliferative effects
Renal effects
Other effects
Effects on fibrinolytic balance
Side-effects
Contraindications
Drug interactions
Dosing
Clinical efficacy and practical use
Heart failure
Target dose
ACE-I compared with angiotensin receptor blockers
Asymptomatic left ventricular systolic dysfunction
Diastolic failure
Acute myocardial infarction
Hypertension
Secondary prevention and high-risk of cardiovascular disease
Prevention of sudden cardiac death
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. A. Saha, J. Molnar, and R. R. Arora Tissue ACE Inhibitors for Secondary Prevention of Cardiovascular Disease in Patients With Preserved Left Ventricular Function: A Pooled Meta-analysis of Randomized Placebo-controlled Trials Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 192 - 204. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Tendera Introduction Eur. Heart J. Suppl., September 1, 2007; 9(suppl_E): E1 - E1. [Full Text] [PDF]
|
|
|
|
 |
|
 W S A Smellie, J Forth, J J Coleman, W Irvine, P C Dore, G Handley, D G Williams, P J Galloway, K G Kerr, R Herriot, et al. Best practice in primary care pathology: review 6 J. Clin. Pathol., March 1, 2007; 60(3): 225 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cardinale, A. Colombo, M. T. Sandri, G. Lamantia, N. Colombo, M. Civelli, G. Martinelli, F. Veglia, C. Fiorentini, and C. M. Cipolla Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition Circulation, December 5, 2006; 114(23): 2474 - 2481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Lucas, G A Christie, and W S Waring Rapid onset of haemodynamic effects after angiotensin converting enzyme-inhibitor overdose: implications for initial patient triage. Emerg. Med. J., November 1, 2006; 23(11): 854 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfeffer and E. D. Frohlich Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2021 - H2025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C Shah, S. Pringle, and A. Struthers Aldosterone Blockade Over and Above ACE-Inhibitors in Patients with Coronary Artery Disease but without Heart Failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1): 20 - 30. [Abstract] [PDF]
|
|
|
|
 |
|
 M. H. Strauss, S. Verma, J. Schrader, S. Luders, A. Kulschewski, F. Hammersen, K. Plate, J. Berger, W. Zidek, P. Dominiak, et al. MOSES Raises Questions * Response: Stroke, February 1, 2006; 37(2): 338 - 340. [Full Text] [PDF]
|
|
|
|
 |
|
 D M Shavelle Are angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis? Heart, October 1, 2005; 91(10): 1257 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tendera Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe Eur. Heart J. Suppl., October 1, 2005; 7(suppl_J): J5 - J9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.V. McMurray The role of angiotensin II receptor blockers in the management of heart failure Eur. Heart J. Suppl., October 1, 2005; 7(suppl_J): J10 - J14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Maggioni Review of the new ESC guidelines for the pharmacological management of chronic heart failure Eur. Heart J. Suppl., October 1, 2005; 7(suppl_J): J15 - J20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Verma, L. A. Leiter, E. M. Lonn, and M. H. Strauss Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE Eur. Heart J., July 2, 2005; 26(14): 1347 - 1349. [Full Text] [PDF]
|
|
|
|
|
|
K Swedberg What can we learn from Europe? Heart, May 1, 2005; 91(suppl_2): ii21 - ii23. [Abstract] [Full Text] [PDF]
|
|